Buscar
« Anterior |
1 - 10 de 13
|
Siguiente »
Resultados de la búsqueda
Select an image to start the slideshow
EZH2 and STING as therapeutic targets in immunologically cold breast and lung tumors
1 of 10
Fine-Tuning Fate: VIP and VIP Receptors as Dynamic Rheostats in Pancreatic Cancer
2 of 10
Mechanisms of efficacy and toxicity of immune checkpoint inhibitors in human cancer patients
3 of 10
Synergistic Paradigm of Radiotherapy and PD-L1 Blockade Orchestrates the Induction of Stem-Like T Cell Populations within the Tumor-Draining Lymph Node
4 of 10
Engineering Armored CAR T Cells to Secrete Functional VIPR Antagonist
5 of 10
Tumor Membrane Vesicles as a Personalized Vaccine Immunotherapy Platform for Cancer
6 of 10
Differentiation of CD8 T cells during chronic viral infection
7 of 10
Intertumoral and Intratumoral Heterogeneity of Cancer: Types, Causes, Detection, and Clinical Implications
8 of 10
Inhibiting VIP Receptor Signaling Promotes T Cell Mediated Immune Response in Murine Melanoma Models
9 of 10
Development of a Tumor Membrane-based Vaccine for Breast Cancer, Studied as a Monotherapy and in Combination with Immune Checkpoint Blockade Antibodies
10 of 10